NEW YORK, NY / ACCESSWIRE / October 16, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Blink Charging Company (NASDAQ:BLNK)
Class Period: March 6, 2020 - August 19, 2020
Lead Plaintiff Deadline: October 23, 2020
The BLNK lawsuit alleges that Blink Charging Company made materially false and/or misleading statements and/or failed to disclose that: (i) many of Blink's charging stations are damaged, neglected, non-functional, inaccessible, nor non-accessible; (ii) Blink's purported partnerships and expansions with other companies were overstated; (iii) the purported growth of the Company's network has been overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in BLNK: http://www.kleinstocklaw.com/pslra-1/blink-charging-company-loss-submission-form?id=10240&from=1
Nano-X Imaging Ltd. (NASDAQ:NNOX)
Class Period: August 21, 2020 - September 15, 2020
Lead Plaintiff Deadline: November 16, 2020
Nano-X Imaging Ltd. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in NNOX: http://www.kleinstocklaw.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?id=10240&from=1
Mesoblast Limited (NASDAQ:MESO)
Class Period: April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline: December 7, 2020
The MESO lawsuit alleges that throughout the class period, Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid-refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in MESO: http://www.kleinstocklaw.com/pslra-1/mesoblast-limited-loss-submission-form?id=10240&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899, or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm